Associations between perfluoroalkyl substances and the severity of non-alcoholic fatty liver disease.

Autor: David N; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France., Antignac JP; Oniris, INRAE, LABERCA, Nantes, France., Roux M; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Marchand P; Oniris, INRAE, LABERCA, Nantes, France., Michalak S; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France; Service d'Anatomopathologie, Centre Hospitalier Universitaire d'Angers, Angers, France., Oberti F; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Fouchard I; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Lannes A; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Blanchet O; Centre de Ressources Biologiques BB-0033-00038, Centre Hospitalier Universitaire d'Angers, Angers, France., Cales P; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Blanc EB; Université Paris Cité, T3S, Inserm UMR, S-1124, F-75006 Paris, France., Boursier J; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France., Canivet CM; Service d'Hépato-Gastroentérologie et Oncologie Digestive, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire HIFIH, SFR ICAT 4208, Université d'Angers, Angers, France. Electronic address: clemence.canivet@chu-angers.fr.
Jazyk: angličtina
Zdroj: Environment international [Environ Int] 2023 Oct; Vol. 180, pp. 108235. Date of Electronic Publication: 2023 Sep 27.
DOI: 10.1016/j.envint.2023.108235
Abstrakt: Background: Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide and the determinants driving its severity remain to be elucidated. Perfluoroalkyl substances (PFAS) are synthetic chemical compounds. They are used in commonplace products and persistent in water, soil and the human body. In vitro and animal studies suggest a pathogenic role for PFAS in metabolic diseases such as NAFLD.
Objectives: We aimed to evaluate the association between NAFLD severity and serum PFAS concentrations in humans.
Methods: One hundred biopsy-proven NAFLD patients were included with a well-balanced distribution between the different stages of severity: 25 patients with simple steatosis, 25 with early non-alcoholic steatohepatitis (NASH and F0-F1 fibrosis), 33 with fibrotic NASH (NASH and F2-F3 fibrosis), and 17 with cirrhotic NASH (NASH and F4 fibrosis). Liver histological features were evaluated according to the NASH Clinical Research Network classification. Seventeen PFAS were measured by high-performance liquid chromatography coupled with tandem mass spectrometry on serum samples stored at -80 °C.
Results: The median age was 60 years, 61 % of patients were male, 46 % had diabetes and the median body mass index (BMI) was 32 kg/m 2 . Long-chain PFAS were associated with steatosis grade (p = 0.03). Among the nine PFAS detected in > 50 % of the patients, Perfluoro-n-heptanoic acid (PFHpA) showed significantly higher concentrations in grade 3 steatosis versus grade 1 (p = 0.02). Perfluoro-n-dodecanoic acid (PFDoA) concentrations were higher in patients with significant fibrosis (p = 0.04) and PFHpA in patients with advanced fibrosis (p = 0.02). The association between PFHpA and steatosis grade remained significant in multivariate analysis adjusted for age, gender, BMI, diabetes presence and dyslipidemia (p = 0.004).
Discussion: Our study showed a significant association between PFHpA and liver steatosis in NAFLD. According to data available in the literature, PFHpA could be implicated in liver steatosis through β-oxidation and biosynthesis of fatty acids.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Clemence CANIVET reports financial support was provided by Association Francaise d’étude du foie.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: